I've stopped trying to count just how long Boston Scientific (NYSE:BSX) has been a "turnaround" story in the med-tech space, because frankly it feels like waiting for Godot. This company paid a huge amount of money to enter two markets right before major slowdowns and no combination of acquisitions, restructurings or buzzwords has managed to deliver any sort of exciting consistent free cash flow growth.
A Second Quarter Worse Than Mediocre
This has not been a great second quarter across the medical device space, as economic issues have kept patients away from their doctors and hospitals have pushed back hard on price inflation. Even against a backdrop of challenging volumes at rivals like Johnson & Johnson (NYSE:JNJ), Bard (NYSE:BCR), Stryker (NYSE:SYK) and St. Jude (NYSE:STJ), Boston Scientific did not stand out positively.
Read the full piece below:
http://stocks.investopedia.com/stock-analysis/2011/The-Perpetual-Boston-Scientific-Turnaround-Story-BSX-JNJ-MDT-STJ-ABT-COV-VOLC0804.aspx
No comments:
Post a Comment